Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

CEO

Mr. Fredrik Tiberg

Employees

267

Country

ISIN

SE0007692850

Listings

0 Comments

Share your thoughts

FAQ

What is Camurus AB stock price today?▼

The current price of 0RD1.LSE is SEK696 SEK — it has increased by +1.61% in the past 24 hours. Watch Camurus AB stock price performance more closely on the chart.

What is Camurus AB stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Camurus AB stocks are traded under the ticker 0RD1.LSE.

What is Camurus AB market cap?▼

Today Camurus AB has the market capitalization of 41.65B

When is the next Camurus AB earnings date?▼

Camurus AB is going to release the next earnings report on February 12, 2026.

What were Camurus AB earnings last quarter?▼

0RD1.LSE earnings for the last quarter are 3.31 SEK per share, whereas the estimation was 3.34 SEK resulting in a -0.83% surprise. The estimated earnings for the next quarter are N/A SEK per share.

What is Camurus AB revenue for the last year?▼

Camurus AB revenue for the last year amounts to 3.74B SEK.

What is Camurus AB net income for the last year?▼

0RD1.LSE net income for the last year is 856.79M SEK.

How many employees does Camurus AB have?▼

As of February 09, 2026, the company has 267 employees.

In which sector is Camurus AB located?▼

Camurus AB operates in the Industrials sector.

When did Camurus AB complete a stock split?▼

Camurus AB has not had any recent stock splits.

Where is Camurus AB headquartered?▼

Camurus AB is headquartered in Lund, SE.